Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 9/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23771192 | 0.98 | TSHR (0.50) | TSHRCHRNB2CHRNA4CHRNB4MEN1 | |
| Bromide SCHEMBL17746921 | 0.80 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4KMT2ACHRNA3 | |
| Iodide SCHEMBL29902225 | 0.78 | CHRNB2 (0.47) | TSHRCHRNB2CHRNA4CHRNB4MEN1 | |
| SCHEMBL23771144 | 0.78 | TSHR (0.46) | TSHRCHRNB2CHRNA4CHRNB4MEN1 | |
| Bromide SCHEMBL1671800 | 0.76 | TSHR (0.44) | TSHRCHRNB2CHRNA4CHRNB4MEN1 | |
| SCHEMBL9774513 | 0.76 | CHRNB2 (0.42) | TSHRCHRNB2CHRNA4CHRNB4MEN1 | |
| SCHEMBL15876329 | 0.75 | TSHR (0.48) | TSHRMEN1KMT2ASLC1A1 | |
| SCHEMBL125808 | 0.75 | — | — | |
| SCHEMBL18116497 | 0.74 | SLC1A1 (0.45) | TSHRCHRNB2CHRNA4CHRNB4MEN1 | |
| SCHEMBL12410073 | 0.73 | TSHR (0.46) | TSHRCHRNB2CHRNA4CHRNB4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573882-B2 | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | JSC GRINDEKS (LV) | 2017-02-21 | — | — | US | disclosed |
| US-20160137589-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | JSC GRINDEKS (LV) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137589-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | FABP3, ABAT, BBOX1 | TSHR 4548/4885CHRNB2 1156/4885CHRNA4 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.